Protocol Ledger

NCT06466785 · Phase III · RECRUITING

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Interventional Phase III clinical trial protocol NCT06466785 sponsored by Genexine in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-25 Enrollment: 429 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06466785
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)429 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06466785
Protocol FieldVerified Registry Value
NCT IdentifierNCT06466785
Consolidated Lead SponsorGenexine
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment429 participants (ESTIMATED)
Registered Start Date2024-01-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06466785
Hospital Research SiteLocationSite Profile
Taipei Medical University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI